Kathleen Pritchard, MD

Founding Editor

Dr. Pritchard is a medical oncologist and clinical trials research scientist. Her areas of interest include multi-center clinical trials; adjuvant, biologic and hormonal therapy for breast cancer; correlative and translational research in breast cancer; banking of tumor, tissue, serum and data; and predictive and prognostic factors in breast cancer.

In 2005, Dr. Pritchard was awarded the O. Harold Warwick Prize for Cancer Control in Canada by the Canadian Cancer Society and the National Cancer Institute of Canada for her work in clinical and translational trials in breast cancer.

As chair of the National Cancer Institute of Canada Clinical Trials Breast Cancer Site Group (now Canadian Cancer Trials Group), Dr. Pritchard has guided the development and performance of multi-center Canadian clinical trials of new therapies for women with breast cancer for more than 25 years.

Her research has included clinical trials and translational approaches in the areas of adjuvant therapy, hormonal therapy, chemotherapy and optimal locoregional therapy for breast cancer. She has also been a member of the team conducting prevention trials comparing tamoxifen and raloxifene.

Dr. Pritchard holds a major leadership role in national and international multi-center clinical trials. She is a frequent consultant for scientific and clinical groups, and a member of scientific advisory boards and independent data monitoring committees for clinical trials worldwide.

Dr. Pritchard is also widely published, including in The New England Journal of Medicine, Journal of the National Cancer Institute, The Journal of Clinical Oncology, The Lancet, and The Lancet Oncology. Dr. Pritchard serves on the editorial boards of the Journal of Clinical Oncology, European Journal of Cancer, The Oncologist, Clinical Breast Cancer and The Breast.

According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.

Edith A. Perez, MD

Editor-in-Chief

Edith Perez, MD, is the Serene M. and Frances C. Durling Professor of Medicine at Mayo Clinic College of Medicine. Dr. Perez is a cancer specialist and an internationally-known translational researcher. Her roles extend nationally, including group vice chair of the Alliance for Clinical Trials in Oncology and other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute.

Dr. Perez has authored more than 700 research articles in journals, books and abstracts and is invited frequently to lecture at national and international meetings. Dr. Perez serves on the editorial boards of multiple academic journals.

Dr. Perez is developing a wide range of clinical trials exploring targeted therapeutic agents for the treatment and prevention of breast cancer. She is also leading studies to evaluate the role of genetic biomarkers in the development, aggressiveness and therapeutic efficacy of therapies for breast cancer.

John Bartlett BSc, PhD

Scientific Editor

Pr. John Bartlett’s research is focused on the development of novel diagnostic approaches to stratified medicine predominantly in breast and prostate cancer. He is developing and validating novel approaches to molecular diagnostics in cancer. He is the author of over 125 papers. Dr John Bartlett is also involved in the TRANSBIG research network and in scientific working groups as part of the Breast International Group (BIG) network.

Personalized medicine requires personalized diagnostics. As the impact of the deep molecular characterization of cancer and other diseases is translated into clinical management of patients a new wave of molecular diagnostic tools are emerging. Dr. John Bartlett’s research is focused on the development of novel diagnostic approaches to stratified medicine predominantly in breast and prostate cancer. By deep molecular analysis across large clinical cohorts, linked to mechanistic understanding of pathways driving therapeutic resistance, he is developing and validating novel approaches to molecular diagnostics in cancer. These novel approaches will increasingly enable a personalized or stratified treatment approach, in the clinical setting, for cancer patients across Ontario and beyond.

• Program Director, Diagnostic Development, OICR
• Honorary Professor, College of Medicine and Veterinary Medicine, University of Edinburgh
• Provincial Principal Investigator, Ontario Tumour Bank
• Affiliate Scientist, University Health Network, Toronto
• Professor (Status-Only), Department of Laboratory Medicine and Pathobiology, University of Toronto

The author of over 125 papers. Dr. John Bartlett is also involved in the TRANSBIG research network and in scientific working groups as part of the Breast International Group (BIG) network.